GALECTIN THERAPEUTICS INC. Finance Lease, Right-of-Use Asset, Amortization
GALECTIN THERAPEUTICS INC. (GALT) reported Finance Lease, Right-of-Use Asset, Amortization of $20.00 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2021-08-16
- GALECTIN THERAPEUTICS INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-06-30 was $10.00K, a 25.00% increase year-over-year.
- GALECTIN THERAPEUTICS INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-03-31 was $10.00K, a 11.11% increase year-over-year.
- GALECTIN THERAPEUTICS INC. finance lease, right-of-use asset, amortization for the quarter ending 2020-12-31 was $9.00K, a 0.00% change year-over-year.
- GALECTIN THERAPEUTICS INC. finance lease, right-of-use asset, amortization for the quarter ending 2020-09-30 was $10.00K, a 25.00% increase year-over-year.
- GALECTIN THERAPEUTICS INC. finance lease, right-of-use asset, amortization for fiscal 2020 was $36.00K, a 2.86% increase from fiscal 2019.
- GALECTIN THERAPEUTICS INC. finance lease, right-of-use asset, amortization for fiscal 2019 was $35.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2021-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $20.00K 10-Q · filed 2021-08-16 | $29.00K derived: sum of 3 quarters · filed 2021-08-16 | $39.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | $10.00K 10-Q · filed 2021-05-17 | $19.00K derived: sum of 2 quarters · filed 2021-05-17 | $29.00K derived: sum of 3 quarters · filed 2021-05-17 | $37.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $19.00K derived: sum of 2 quarters · filed 2021-03-31 | $27.00K derived: sum of 3 quarters · filed 2021-08-16 | $36.00K 10-K · filed 2021-03-31 |
| 2020-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $18.00K derived: sum of 2 quarters · filed 2021-08-16 | $27.00K 10-Q · filed 2020-11-09 | $36.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $17.00K 10-Q · filed 2021-08-16 | $26.00K derived: sum of 3 quarters · filed 2021-08-16 | $34.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $9.00K 10-Q · filed 2021-05-17 | $18.00K derived: sum of 2 quarters · filed 2021-05-17 | $26.00K derived: sum of 3 quarters · filed 2021-05-17 | $34.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $17.00K derived: sum of 2 quarters · filed 2021-03-31 | $25.00K derived: sum of 3 quarters · filed 2021-03-31 | $35.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $16.00K derived: sum of 2 quarters · filed 2020-11-09 | $26.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $18.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $10.00K 10-Q · filed 2020-05-11 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |